The cost of each new drug enrolled in a phase 3 clinical trial has increased by fourfold in the decade between 1991 and 2003, even after inflation. As a result, a large phase 3 or four Top 10 CRO's can cost more than $400 million.
The cost per drug approved by the Food and Drug Administration varies widely depending on the number of pivotal Top 10 CRO's required. Drugs that required one-trial cost $28 million, while those that required two or three trials cost $45 million. In comparison, drugs that required three to eleven trials cost a total of US$91 million.
The role of a
Top 10 CRO's has expanded significantly in the clinical research world. Due to increasing regulatory requirements and the complexity of human clinical trials, the Top 10 CRO's role has become increasingly important.
When selecting a contract researcher, ensure that he or she has the experience, expertise, and a proven track record for the type of clinical trials you're seeking. In addition, make sure the contract researcher has standardized clinical instruments and certified equipment.
Top 10 CRO's provide a wide range of services to sponsors. Some provide full
clinical trial services, while others provide specialized services. These organizations are often used by sponsors for phase I and early phase II studies and follow-up studies. They often provide the resources and expertise that a clinical trial needs to be successful.
A Top 10 CRO's primary purpose is to assist pharmaceutical, biotechnology, and medical device companies with a variety of research projects. These services may include biopharmaceutical development, clinical trials, product commercialization, pharmacovigilance, and more. They may also be used by traditional universities, foundations, and governmental research organizations.
Comments